|
1
|
Rogueda PG and Traini D: The nanoscale in
pulmonary delivery. Part 1: Deposition, fate, toxicology and
effects. Expert Opin Drug Deliv. 4:595–606. 2007.
|
|
2
|
Cooper DL, Conder CM and Harirforoosh S:
Nanoparticles in drug delivery: Mechanism of action, formulation
and clinical application towards reduction in drug-associated
nephrotoxicity. Expert Opin Drug Deliv. 11:1661–1680. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yuan Y, Cai T, Xia X, Zhang R, Chiba P and
Cai Y: Nanoparticle delivery of anticancer drugs overcomes
multidrug resistance in breast cancer. Drug Deliv. 23:3350–3357.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jia F, Liu X, Li L, Mallapragada S,
Narasimhan B and Wang Q: Multifunctional nanoparticles for targeted
delivery of immune activating and cancer therapeutic agents. J
Control Release. 172:1020–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y, Pan J and Feng SS: Nanoparticles of
lipid monolayer shell and biodegradable polymer core for controlled
release of paclitaxel: Effects of surfactants on particles size,
characteristics and in vitro performance. Int J Pharm. 395:243–250.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mandal B, Bhattacharjee H, Mittal N, Sah
H, Balabathula P, Thoma LA and Wood GC: Core-shell-type
lipid-polymer hybrid nanoparticles as a drug delivery platform.
Nanomedicine (Lond). 9:474–491. 2013. View Article : Google Scholar
|
|
7
|
Vyas S, Rai S, Paliwal R, Gupta PN, Khatri
K, Goyal AK and Vaidya B: Solid lipid nanoparticles (SLNs) as a
rising tool in drug delivery science: One step up in
nanotechnology. Curr Nanosci. 4:30–44. 2008. View Article : Google Scholar
|
|
8
|
Cheow WS and Hadinoto K: Factors affecting
drug encapsulation and stability of lipid-polymer hybrid
nanoparticles. Colloids Surf B Biointerfaces. 85:214–220. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mukherjee B, Satapathy BS, Mondal L, Dey
NS and Maji R: Potentials and challenges of active targeting at the
tumor cells by engineered polymeric nanoparticles. Curr Pharm
Biotechnol. 14:1250–1263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thevenot J, Troutier AL, David L, Delair T
and Ladavière C: Steric stabilization of lipid/polymer particle
assemblies by poly(ethylene glycol)-lipids. Biomacromolecules.
8:3651–3660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Zhu D, Dong X, Sun H, Song C,
Wang C and Kong D: Folate-modified lipid-polymer hybrid
nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine.
10:2101–2114. 2015.PubMed/NCBI
|
|
12
|
Feng S-S and Chien S: Chemotherapeutic
engineering: Application and further development of chemical
engineering principles for chemotherapy of cancer and other
diseases. Chem Eng Sci. 58:4087–4114. 2003. View Article : Google Scholar
|
|
13
|
Chan JM, Zhang L, Yuet KP, Liao G, Rhee
JW, Langer R and Farokhzad OC: PLGA-lecithin-PEG core-shell
nanoparticles for controlled drug delivery. Biomaterials.
30:1627–1634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsieh MJ, Chen MK, Yu YY, Sheu GT and
Chiou HL: Psoralen reverses docetaxel-induced multidrug resistance
in A549/D16 human lung cancer cells lines. Phytomedicine.
21:970–977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang J, Wang X, Cheng K, Zhao W, Hua Y,
Xu C and Yang Z: Psoralen reverses the P-glycoprotein-mediated
multidrug resistance in human breast cancer MCF-7/ADR cells. Mol
Med Rep. 13:4745–4750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai J, Chen S, Zhang W, Hu S, Lu J, Xing J
and Dong Y: Paeonol reverses paclitaxel resistance in human breast
cancer cells by regulating the expression of transgelin 2.
Phytomedicine. 21:984–991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jambhrunkar S, Qu Z, Popat A, Karmakar S,
Xu C and Yu C: Modulating in vitro release and solubility of
griseofulvin using functionalized mesoporous silica nanoparticles.
J Colloid Interface Sci. 434:218–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeong H, Samdani KJ, Yoo DH, Lee DW, Kim
NH, Yoo IS and Lee JH: Resveratrol cross-linked chitosan loaded
with phospholipid for controlled release and antioxidant activity.
Int J Biol Macromol. 93:757–766. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tahir N, Madni A, Balasubramanian V,
Rehman M, Correia A, Kashif PM, Mäkilä E, Salonen J and Santos HA:
Development and optimization of methotrexate-loaded lipid-polymer
hybrid nanoparticles for controlled drug delivery applications. Int
J Pharm. 533:156–168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ,
Radovic-Moreno AF, Alexis F, Langer R and Farokhzad OC:
Self-assembled lipid - polymer hybrid nanoparticles: A robust drug
delivery platform. ACS Nano. 2:1696–1702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mu L and Feng SS: Vitamin E TPGS used as
emulsifier in the solvent evaporation/extraction technique for
fabrication of polymeric nanospheres for controlled release of
paclitaxel (Taxol). J Control Release. 80:129–144. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ruan G and Feng SS: Preparation and
characterizations of PLA-PEG-PLA micro-spheres for controlled
release of paclitaxel. Biomaterials. 24:5037–5044. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abaza M and Luqmani YA: The influence of
pH and hypoxia on tumor metastasis. Expert Rev Anticancer Ther.
13:1229–1242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schornack PA and Gillies RJ: Contributions
of cell metabolism and H+ diffusion to the acidic pH of
tumors. Neoplasia. 5:135–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saraswathy M and Gong S: Different
strategies to overcome multidrug resistance in cancer. Biotechnol
Adv. 31:1397–1407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Åslund AKO, Sulheim E, Snipstad S, von
Haartman E, Baghirov H, Starr N, Kvåle Løvmo M, Lelú S, Scurr D,
Davies CL, et al: Quantification and qualitative effects of
different PEGylations on Poly(butyl cyanoacrylate) Nanoparticles.
Mol Pharm. 14:2560–2569. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harris JM and Chess RB: Effect of
pegylation on pharmaceuticals. Nat Rev Drug Discov. 2:214–221.
2003. View
Article : Google Scholar : PubMed/NCBI
|
